A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat
Background/Objective: Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC). Case Report: A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal ma...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | AACE Clinical Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2376060524001147 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527987117228032 |
|---|---|
| author | Kathleen R. Ruddiman, DO Catherine E. Price, MD, ECNU, FACE Alexander K. Bonnecaze, MD |
| author_facet | Kathleen R. Ruddiman, DO Catherine E. Price, MD, ECNU, FACE Alexander K. Bonnecaze, MD |
| author_sort | Kathleen R. Ruddiman, DO |
| collection | DOAJ |
| description | Background/Objective: Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC). Case Report: A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal mass and hypercortisolism. Right adrenalectomy was pursued with pathology consistent with diagnosis of ACC. Three months after surgery, hypercortisolemia recurred and bony metastatic disease was detected soon after. The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia. The patient’s urinary free cortisol became severely elevated, and osilodrostat was subsequently initiated for steroidogenesis inhibition. As dosage was increased, the patient presented with fatigue and hypotension and was diagnosed with adrenal insufficiency. This was managed with hydrocortisone in a block-and-replace dosing strategy. Discussion: ACC can cause severe hypercortisolism, which is associated with significant morbidity and mortality. Osilodrostat was an effective off-label option for steroidogenesis inhibition in our patient who developed severe hypercortisolism and did not tolerate first-line therapy. Our patient also experienced iatrogenic adrenal insufficiency during treatment with osilodrostat, which was successfully managed using a block-and-replace strategy. There are limited cases currently available that document use of osilodrostat under the above circumstances. Conclusion: Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency. |
| format | Article |
| id | doaj-art-6ea9c93b3d39406bb8d26ec534e3cc6d |
| institution | Kabale University |
| issn | 2376-0605 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | AACE Clinical Case Reports |
| spelling | doaj-art-6ea9c93b3d39406bb8d26ec534e3cc6d2025-01-15T04:11:45ZengElsevierAACE Clinical Case Reports2376-06052025-01-011115357A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With OsilodrostatKathleen R. Ruddiman, DO0Catherine E. Price, MD, ECNU, FACE1Alexander K. Bonnecaze, MD2Division of Endocrinology, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina; Address correspondence to Dr Kathleen R. Ruddiman, Division of Endocrinology, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, North Carolina, Medical Center Blvd, Winston-Salem, NC 27157.Division of Endocrinology, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, North CarolinaDepartment of Endocrinology, Pinehurst Medical Clinic, Pinehurst, North CarolinaBackground/Objective: Osilodrostat used with block-and-replace dosing regimen is an off-label alternative to traditional management of Cushing syndrome due to adrenocortical carcinoma (ACC). Case Report: A 70-year-old woman presented with abdominal pain and was found to have a large right adrenal mass and hypercortisolism. Right adrenalectomy was pursued with pathology consistent with diagnosis of ACC. Three months after surgery, hypercortisolemia recurred and bony metastatic disease was detected soon after. The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia. The patient’s urinary free cortisol became severely elevated, and osilodrostat was subsequently initiated for steroidogenesis inhibition. As dosage was increased, the patient presented with fatigue and hypotension and was diagnosed with adrenal insufficiency. This was managed with hydrocortisone in a block-and-replace dosing strategy. Discussion: ACC can cause severe hypercortisolism, which is associated with significant morbidity and mortality. Osilodrostat was an effective off-label option for steroidogenesis inhibition in our patient who developed severe hypercortisolism and did not tolerate first-line therapy. Our patient also experienced iatrogenic adrenal insufficiency during treatment with osilodrostat, which was successfully managed using a block-and-replace strategy. There are limited cases currently available that document use of osilodrostat under the above circumstances. Conclusion: Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency.http://www.sciencedirect.com/science/article/pii/S2376060524001147osilodrostatblock-and-replaceCushing syndromehypercortisolismadrenocortical carcinoma |
| spellingShingle | Kathleen R. Ruddiman, DO Catherine E. Price, MD, ECNU, FACE Alexander K. Bonnecaze, MD A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat AACE Clinical Case Reports osilodrostat block-and-replace Cushing syndrome hypercortisolism adrenocortical carcinoma |
| title | A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat |
| title_full | A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat |
| title_fullStr | A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat |
| title_full_unstemmed | A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat |
| title_short | A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat |
| title_sort | case of severe cushing syndrome due to metastatic adrenocortical carcinoma treated with osilodrostat |
| topic | osilodrostat block-and-replace Cushing syndrome hypercortisolism adrenocortical carcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2376060524001147 |
| work_keys_str_mv | AT kathleenrruddimando acaseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat AT catherineepricemdecnuface acaseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat AT alexanderkbonnecazemd acaseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat AT kathleenrruddimando caseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat AT catherineepricemdecnuface caseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat AT alexanderkbonnecazemd caseofseverecushingsyndromeduetometastaticadrenocorticalcarcinomatreatedwithosilodrostat |